Dotmatics

Dotmatics is a developer of research and development software that aims to empower scientists throughout the research process. The company provides an enterprise platform that connects science, data, and decision-making, enhancing efficiency and accelerating innovation. Its software enables scientists and students to analyze data effectively, create 2D graphs, and simplify various tasks related to data analysis, statistics, and graphing. By offering tools tailored to the needs of researchers, Dotmatics facilitates a more streamlined approach to scientific inquiry and development.

Thomas Swalla

CEO and Board Member

15 past transactions

Virscidian

Acquisition in 2024
Virscidian specializes in custom analytical software solutions to fit natural laboratory workflows.

BioGlyph

Corporate Round in 2024
BioGlyph aims to enhance and expedite biologics discovery and development.

EasyPanel

Acquisition in 2024
EasyPanel specializes in innovative flow cytometry product panel design software.

M-Star Simulations

Acquisition in 2024
M-Star Simulations is a software company that focuses on the development of computational fluid dynamics software tailored for the chemical, biopharmaceutical, and energy sectors. The company provides tools that facilitate the simplified setup and execution of complex fluid dynamics simulations. This enables users to optimize engineering and biological processes in a simulated environment, allowing for enhanced decision-making and efficiency before actual implementation in the physical world. By offering these advanced simulation capabilities, M-Star Simulations supports industries in improving their operational effectiveness and innovation.

Omiq

Acquisition in 2021
Omiq is a developer of a modern cytometry analysis platform that integrates machine learning with traditional analytical methods. The platform offers a flexible, modular workflow, allowing researchers to conduct their entire analysis from raw data to statistical significance within a single software environment. It combines users' expertise with advanced computational techniques and visualizations, facilitating deeper insights from complex data. The platform also includes a wide range of customizable high-parameter analysis algorithms that can be easily imported and updated, enabling researchers to effectively identify drug or therapeutic interactions by tracking biomarkers in laboratory samples.

Protein Metrics

Acquisition in 2021
Protein Metrics is a software that analyzes mass spectrometry, chromatography, and capillary electrophoresis data sets for research. It creates software tools for protein characterization to match the rapidly innovating hardware tools created by the leading scientific instrument companies. The company was founded in 2011 and is based in Cupertino, California.

LabArchives

Acquisition in 2021
LabArchives offers a web-based software solution for the storage, organization, sharing, and publishing of scientific data, serving as more than just an Electronic Laboratory Notebook (ELN). It functions as a collaborative platform that enables research scientists to manage and document their data effectively. The cloud-based application supports secure collaboration, automates data capture, and enhances workflows, thereby improving overall lab efficiency. LabArchives also provides a locally installed version of its software and offers a special Student Edition for high school and undergraduate students, promoting accessibility and education in scientific research. The platform is utilized by scientists globally as a comprehensive information hub for research labs.

De Novo Software

Acquisition in 2021
De Novo Software is a company specializing in flow cytometry data analysis solutions, primarily known for its product FCS Express, which is recognized as one of the fastest-growing tools in the industry. The software aims to facilitate the analysis of flow cytometry data, bridging the gap between image cytometry and actionable results. De Novo’s custom data analysis solutions support scientists and researchers throughout the drug development pipeline, enabling them to efficiently extract insights from raw data in a timely manner.

Biobright

Acquisition in 2020
BioBright LLC is a scientific lab data automation company based in Boston, Massachusetts, established in 2013. Dedicated to advancing data-centric research, BioBright develops solutions that facilitate the automation of data collection from both internal and external sources. The company's platform allows scientists to standardize and analyze critical experimental data, ensuring that validation and integrity checks are incorporated into the process. As of June 30, 2020, BioBright operates as a subsidiary of Dotmatics Limited, continuing its mission to create a smarter laboratory environment through innovative automation technologies.

nQuery

Acquisition in 2020
nQuery is a search engine for your data.

Cytapex

Acquisition in 2020
Cytapex Bioinformatics Inc. is a bioinformatics contract research organization based in Burnaby, Canada, that specializes in developing automated data analysis pipelines for cytometry data. Since its incorporation in 2016, Cytapex has focused on providing expert consulting services in data management, quality control, and data analysis. The company offers customized solutions for gating and biomarker discovery, tailored for complex panels used in clinical trials and diagnostics. Its algorithms are designed to deliver rapid, robust, and reproducible data-driven results, enabling clients to demonstrate the feasibility of automated analysis, identify low-quality samples, and assess dimly expressed biomarkers. As of May 2020, Cytapex operates as a subsidiary of Insightful Science, LLC.

SnapGene

Acquisition in 2019
SnapGene offers the fastest and easiest way to plan, visualize, and document DNA cloning and PCR.

Geneious

Acquisition in 2019
Geneious is an applied bioinformatics company that offers a software platform designed for the biopharmaceutical industry. This platform provides a comprehensive suite of tools for analyzing, interpreting, and applying molecular sequence data. By delivering scalable data management and computational capabilities, Geneious enables organizations to enhance their operational efficiencies and expedite the drug discovery process.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.